The Prospects of an Active Vaccine Against Asthma Targeting IL-5

Allergen-specific T helper type 2 (Th2) responses followed by eosinophilic inflammation of the lung are important causes of allergic asthma. Interleukin-5 (IL-5) is a master regulator of eosinophil differentiation as well as activation. Blocking IL-5 using monoclonal antibodies (mAbs) against IL-5 is a powerful way to improve asthmatic symptoms in patients with an eosinophilic component of the disease. We have previously shown that vaccination against IL-5 can abrogate eosinophilic inflammation of the lung in allergic mice. More recently, we have demonstrated that eosinophil-mediated skin disease in horses with insect bite hypersensitivity can be strongly reduced by vaccination against IL-5. Here we would like to propose the development of a similar vaccine for the treatment of asthma in humans.

[1]  T. Kündig,et al.  Active vaccination against interleukin‐5 as long‐term treatment for insect‐bite hypersensitivity in horses , 2018, Allergy.

[2]  T. Kündig,et al.  Treating insect‐bite hypersensitivity in horses with active vaccination against IL‐5 , 2018, The Journal of allergy and clinical immunology.

[3]  M. Bachmann,et al.  Vaccination against IL-31 for the treatment of atopic dermatitis in dogs. , 2018, The Journal of allergy and clinical immunology.

[4]  P. Kuna,et al.  Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma. , 2018, Immunotherapy.

[5]  S. Quirce,et al.  Biologics in the treatment of severe asthma. , 2017, Allergologia et immunopathologia.

[6]  Oliver N Keene,et al.  Biomarkers for severe eosinophilic asthma , 2017, The Journal of allergy and clinical immunology.

[7]  D. Stuart,et al.  Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy , 2017, npj Vaccines.

[8]  I. Pavord,et al.  Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease , 2017, The New England journal of medicine.

[9]  J. FitzGerald,et al.  The safety of mepolizumab for the treatment of asthma , 2017, Expert opinion on drug safety.

[10]  Yanan Cui,et al.  Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system , 2017, Drug development and industrial pharmacy.

[11]  Julie Ducreux,et al.  Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study , 2016, Rheumatology.

[12]  G. Jennings,et al.  Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes. , 2016, Molecular Therapy.

[13]  H. Hammad,et al.  The immunology of asthma , 2014, Nature Immunology.

[14]  K. Schwarz,et al.  Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes , 2014, Molecular therapy. Methods & clinical development.

[15]  F. Houssiau,et al.  Type I interferon blockade in systemic lupus erythematosus: where do we stand? , 2014, Rheumatology.

[16]  P. Erwin,et al.  The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. , 2013, The Journal of allergy and clinical immunology.

[17]  W. Renner,et al.  The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. , 2013, The Journal of allergy and clinical immunology.

[18]  M. Bachmann,et al.  Innate Immunity Mediates Follicular Transport of Particulate but Not Soluble Protein Antigen , 2012, The Journal of Immunology.

[19]  K. Bendtzen,et al.  Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease , 2011, Alimentary pharmacology & therapeutics.

[20]  R. Coffman,et al.  Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. , 2011, Immunity.

[21]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[22]  G. Lipowsky,et al.  Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice. , 2010, Vaccine.

[23]  A. Jegerlehner,et al.  Alveolar Macrophages and Lung Dendritic Cells Sense RNA and Drive Mucosal IgA Responses , 2009, The Journal of Immunology.

[24]  J. Zagury,et al.  Anti-cytokine therapeutics: history and update. , 2009, Current pharmaceutical design.

[25]  S. Holgate,et al.  Treatment strategies for allergy and asthma , 2008, Nature Reviews Immunology.

[26]  A. Jegerlehner,et al.  TLR9 Signaling in B Cells Determines Class Switch Recombination to IgG2a , 2007, The Journal of Immunology.

[27]  G. Jennings,et al.  Vaccination against IL‐17 suppresses autoimmune arthritis and encephalomyelitis , 2006, European journal of immunology.

[28]  Lauren Cohn,et al.  Asthma: mechanisms of disease persistence and progression. , 2004, Annual review of immunology.

[29]  R. Zuwallack,et al.  Direct clinician-to-patient feedback discussion of inhaled steroid use: its effect on adherence. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[30]  P. Foster,et al.  Active Vaccination Against IL-5 Bypasses Immunological Tolerance and Ameliorates Experimental Asthma1 , 2001, The Journal of Immunology.

[31]  M. Feldmann,et al.  Therapeutic antibodies elicited by immunization against TNF-α , 1999, Nature Biotechnology.

[32]  C. Rand,et al.  Nonadherence in asthmatic patients: is there a solution to the problem? , 1997, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[33]  M. Jacobson,et al.  Grass pollen immunotherapy: efficacy and safety during a 4‐year follow‐up study , 1995, Allergy.

[34]  C. Goodnow,et al.  Induction of self-tolerance in T cells but not B cells of transgenic mice expressing little self antigen. , 1991, Science.

[35]  P. Creticos.  Immunotherapy with allergens. , 1987, JAMA.

[36]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[37]  I. Pavord,et al.  Inhaled corticosteroid dose-response on blood eosinophils in asthma - Authors' reply. , 2016, The Lancet. Respiratory medicine.

[38]  Measurement of infliximab and anti-infliximab antibody levels can help distinguish maintenance versus loss of response. , 2012, Gastroenterology & hepatology.

[39]  K. Nakagome,et al.  Allergen immunotherapy in asthma: current status and future perspectives. , 2010, Allergology international : official journal of the Japanese Society of Allergology.

[40]  M. Bachmann,et al.  Therapeutic vaccination for chronic diseases: a new class of drugs in sight , 2004, Nature Reviews Drug Discovery.

[41]  C. Snapper,et al.  T cell-independent antigens type 2. , 1995, Annual review of immunology.

[42]  I. Maclennan,et al.  Germinal centres in T-cell-dependent antibody responses. , 1992, Immunology today.